Table 1.
Summary of demographic and clinical characteristics of LE patients
| Parameters | Groups | IAB+ (n = 41) | AB− (n = 59) | F/χ2 |
|---|---|---|---|---|
| Age (years) | M/SD | 44.6 ± 16.5 | 38.9 ± 13.8 | 3.488 (*) |
| Sex (F) | N (%) | 20 (48.8) | 25 (42.4) | 0.547 n.s. |
| Education (≥ 10 years) | N (%) | 31 (75.0) | 41 (69.5) | 0.449 n.s. |
| IQ | M/SD | 110.5 (15.4) | 106.0 (12.3) | 2.027 n.s. |
| Age at epilepsy onset (years) | M/SD | 37.9 ± 17.6 | 31.6 ± 15.1 | 3.686 (*) |
| Duration of epilepsy (years) | M/SD | 6.6 ± 9.2 | 7.2 ± 7.7 | 0.136 n.s. |
| Number of AEDs | M/SD | 1.5 ± 0.9 | 1.6 ± 1.0 | 0.542 n.s |
| Off drug | N (%) | 6 (14.6) | 10 (16.9) | 0.096 n.s. |
| Monotherapy | N (%) | 14 (34.1) | 16 (27.1) | 0.569 n.s. |
| Polytherapy | N (%) | 21 (51.2) | 33 (55.9) | 0.216 n.s |
| Antidepressants | N (%) | 5 (12.2%) | 4 (6.8%) | 1.785 n.s |
| Neuroleptics | N (%) | – | – | – |
| Number of any Psychoactive drugs | M/SD | 1.6 ± 0.9 | 1.7 ± 1.1 | 0.105 n.s |
| Structural MRI | ||||
| Side | N (%) | 2.664 n.s | ||
| Right | 9 (33) | 13 (34) | ||
| Left | 7 (26) | 16 (42) | ||
| Bilateral | 11 (41) | 9 (24) | ||
| Amygdala affected | N (%) | 21 (51) | 22 (34) | 1.915 n.s |
| Swelling | 17 (81) | 19 (86) | ||
| Atrophy | 3 (14) | 3 (14) | ||
| Hyperintensity | 1 (5) | 0 (0) | ||
| Hippocampus affected | N (%) | 17 (51) | 20 (37) | 0.594 n.s |
| Swelling | 8 (47) | 7 (35) | ||
| Atrophy | 8 (47) | 10 (50) | ||
| Hyperintensity | 1 (6) | 3 (15) | ||
| Seizure frequency | M/SD | 9.2 ± 20.2 | 18.7 ± 58.7 | 0.600 n.s |
L left, R right, M mean, SD standard deviation, n = number, IAB+ intracellular auto-antibody positive, AB− auto-antibodies negative, n.s. not significant
(*)p < 0.1, * p < 0.05 (ANOVA or frequency tabulation with Chi2 test)